Inactivated vaccine candidate protects macaques from SARS-CoV-2 infection

May 06, 2020

In mice, rats, and nonhuman primates, a newly developed SARS-CoV-2 virus vaccine candidate induced antibodies that neutralized several different SARS-CoV-2 strains. Critically, it did so without leading to a phenomenon known as antibody-dependent enhancement (ADE), which previous reports have raised as a concern. Based on the authors' observations, they propose that their vaccine candidate, "PiCoVacc," is safe in macaques and should be explored in clinical trials in humans. Rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Purified inactivated viruses - safe and effective for the prevention of diseases caused by viruses like influenza virus and poliovirus - have been traditionally used for vaccine development. Here, to develop preclinical models for such a SARS-CoV-2 vaccine, Qiang Gao and colleagues isolated an array of virus strains from 11 hospitalized patients from China, Italy, Switzerland, the UK and Spain. One strain was selected and developed into a purified, inactivated vaccine candidate, PiCoVacc. When tested in mice, PiCoVacc could elicit about ten-fold more antibodies against the virus spike protein than were found in serum from the recovered COVID-19 patients, the authors report. In mice and rats vaccinated with PiCoVacc and infected with the ten remaining virus strains three weeks later, PiCoVacc neutralized all strains, the authors say. They next vaccinated macaques at doses of either 1.5 micrograms or 6 micrograms three times over the course of two weeks. When later infected with SARS-CoV-2 strains, the animals who received the 6-microgram dose showed complete protection, and without observable ADE. The possibility that ADE could manifest after antibody titers wane could not be ruled out in this work, the authors note. "Collectively," they say, "these results suggest a path forward for clinical development of SARS-CoV-2 vaccines for use in humans." Clinical trials with PiCoVacc are expected to begin later this year.

American Association for the Advancement of Science

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to